Real-life temocillin use in Greater Paris area, effectiveness and risk factors for failure in infections caused by ESBL-producing Enterobacterales: a multicentre retrospective study.
Journal
JAC-antimicrobial resistance
ISSN: 2632-1823
Titre abrégé: JAC Antimicrob Resist
Pays: England
ID NLM: 101765283
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
06
09
2022
accepted:
05
12
2022
entrez:
5
1
2023
pubmed:
6
1
2023
medline:
6
1
2023
Statut:
epublish
Résumé
Temocillin is a β-lactam that is not hydrolysed by ESBLs. To describe the real-life use of temocillin, to assess its effectiveness in infections caused by ESBL-producing Enterobacterales, and to identify risk factors for treatment failure. Retrospective multicentric study in eight tertiary care hospitals in the Greater Paris area, including patients who received at least one dose of temocillin for ESBL infections from 1 January to 31 December 2018. Failure was a composite criterion defined within 28 day follow-up by persistence or reappearance of signs of infection, and/or switch to suppressive antibiotic treatment and/or death from infection. A logistic regression with univariable and multivariable analysis was performed to identify risks associated with failure. Data on 130 infection episodes were collected; 113 were due to ESBL-producing Enterobacterales. Mean age was 65.2 ± 15.7 years and 68.1% patients were male. Indications were mostly urinary tract infections (UTIs) (85.8%), bloodstream infections (11.5%), respiratory tract infections (RTIs) (3.5%) and intra-abdominal infections (3.5%). Bacteria involved were The main use of temocillin was UTI due to ESBL-producing
Sections du résumé
Background
UNASSIGNED
Temocillin is a β-lactam that is not hydrolysed by ESBLs.
Objectives
UNASSIGNED
To describe the real-life use of temocillin, to assess its effectiveness in infections caused by ESBL-producing Enterobacterales, and to identify risk factors for treatment failure.
Methods
UNASSIGNED
Retrospective multicentric study in eight tertiary care hospitals in the Greater Paris area, including patients who received at least one dose of temocillin for ESBL infections from 1 January to 31 December 2018. Failure was a composite criterion defined within 28 day follow-up by persistence or reappearance of signs of infection, and/or switch to suppressive antibiotic treatment and/or death from infection. A logistic regression with univariable and multivariable analysis was performed to identify risks associated with failure.
Results
UNASSIGNED
Data on 130 infection episodes were collected; 113 were due to ESBL-producing Enterobacterales. Mean age was 65.2 ± 15.7 years and 68.1% patients were male. Indications were mostly urinary tract infections (UTIs) (85.8%), bloodstream infections (11.5%), respiratory tract infections (RTIs) (3.5%) and intra-abdominal infections (3.5%). Bacteria involved were
Conclusions
UNASSIGNED
The main use of temocillin was UTI due to ESBL-producing
Identifiants
pubmed: 36601547
doi: 10.1093/jacamr/dlac132
pii: dlac132
pmc: PMC9798080
doi:
Types de publication
Journal Article
Langues
eng
Pagination
dlac132Investigateurs
Aurélien Dinh
(A)
Clara Duran
(C)
Hugues Michelon
(H)
Rui Batista
(R)
Simrandeep Singh
(S)
Laurène Deconinck
(L)
Chloé Tesmoingt
(C)
Laura Bouadballah
(L)
Matthieu Lafaurie
(M)
Sophie Touratier
(S)
Victoire de Lastours
(V)
Antoine Hamon
(A)
Marie Antignac
(M)
Jérôme Pacanowski
(J)
Clément Ourghanlian
(C)
Raphaël Lepeule
(R)
David Lebeaux
(D)
Marie-Caroline Loustalot
(MC)
Ruxandra Calin
(R)
Jean Baptiste Pain
(JB)
Benjamin Wyplosz
(B)
Alexandre Bleibtreu
(A)
Helga Junot
(H)
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
Références
Clin Microbiol Rev. 2018 Feb 14;31(2):
pubmed: 29444952
Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0205221
pubmed: 35099273
Int J Antimicrob Agents. 2021 Jul;58(1):106361
pubmed: 34000372
J Antimicrob Chemother. 2015 Mar;70(3):891-8
pubmed: 25433006
Drugs. 1985;29 Suppl 5:175-7
pubmed: 3896736
JAC Antimicrob Resist. 2021 Dec 28;4(1):dlab192
pubmed: 34988445
JAC Antimicrob Resist. 2021 Feb 14;3(1):dlab005
pubmed: 34223083
Int J Antimicrob Agents. 2011 May;37(5):415-9
pubmed: 21429716
J Antimicrob Chemother. 2021 Feb 11;76(3):784-788
pubmed: 33254232
J Antimicrob Chemother. 2011 Nov;66(11):2628-31
pubmed: 21810837
Lancet Infect Dis. 2022 Mar;22(3):390-400
pubmed: 34756180
Infection. 2020 Jun;48(3):357-366
pubmed: 32060859
Drugs. 1985;29 Suppl 5:172-4
pubmed: 4029023
J Antimicrob Chemother. 2009 Feb;63(2):243-5
pubmed: 19095679
Drugs. 1985;29 Suppl 5:207-9
pubmed: 4029026
Int J Med Microbiol. 2010 Aug;300(6):371-9
pubmed: 20537585
Future Microbiol. 2019 Jan;14:81-83
pubmed: 30644315
PLoS One. 2021 Mar 10;16(3):e0248177
pubmed: 33690674
J Antimicrob Chemother. 2013 Nov;68(11):2688-9
pubmed: 23828022
Antibiotics (Basel). 2022 Apr 07;11(4):
pubmed: 35453244
J Antimicrob Chemother. 2009 Aug;64(2):431-3
pubmed: 19520716